Skip to content

Comparison of the mean effect of Remifentanil, Methadone, and Sufentanil on Pain and Delirium in Patients with spinal surgery

Comparison of the mean effect of Remifentanil, Methadone, and Sufentanil on Pain and Delirium in Patients with spinal surgery

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221218056854N1
Enrollment
120
Registered
2023-01-23
Start date
2023-01-21
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple fractures of spine, level unspecified. Fracture of spine, level unspecified

Interventions

Intervention 1: Intervention group: patients with spinal surgery whom received Remifentanil Infusion as Remifentanil Hydrochloride I.V. 1mg, sold under the brand name EPAXIR, Exir Pharmaceutical Co. w

Sponsors

Ilam University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with spinal surgery taking Remifentanil Patients with spinal surgery taking Sufentanil Patients with spinal surgery taking Methadone

Exclusion criteria

Exclusion criteria: Patients with Psychological History Patients with History of Drug Addiction Patients with History of Allergic Reaction to Drugs Patients with History of Diabetes Patients with History of Kidney Disease

Design outcomes

Primary

MeasureTime frame
Delirium Severity and Duration. Timepoint: After Spinal Surgery, 6, 12, and 24 Hours After Surgery. Method of measurement: Physical Examination.;Four Main Delirium Features. Timepoint: After Spinal Surgery, 6, 12 and 24 Hours After Surgery. Method of measurement: CAM-ICU(Confusion Assessment Method for the Intensive Care Unit) Questionnaire.;Pain Intensity Score. Timepoint: After Spinal Surgery, 6, 12 and 24 Hours After Surgery. Method of measurement: Visual Analog Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Zanji

Ilam University of Medical Sciences

hamidzanji1997@gmail.com+98 84 3422 4443

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026